Alumis Inc. (ALMS) shares surged nearly 91% on Tuesday to close at $15.87 following the release of positive topline results from its Phase 3 clinical trials.
The stock hit an intraday 52-week high of $22.30 as investors reacted to data for envudeucitinib, the company's oral TYK2 inhibitor designed to treat moderate-to-severe plaque psoriasis.
The massive rally erased months of volatility, with the stock opening at $22.20 against a previous close of $8.31.
According to Investing.com, pre-market gains reached over 144% as trading volumes eventually surged to more than 30 million shares.
This sudden price movement comes as the company prepares to enter a competitive market currently dominated by several large pharmaceutical players.
The trial results appear to have significantly de-risked the company's lead program in the eyes of Wall Street analysts.
Key Takeaways
- ALMS stock surged nearly 91% today following successful Phase 3 ONWARD trials.
- Envudeucitinib met all primary and secondary endpoints with high statistical significance.
- Approximately 65% of patients achieved 90% skin clearance (PASI 90) at Week 24.
- Oppenheimer doubled its price target for Alumis from $25 to $50.
- The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026.
Why Did Alumis (ALMS) Stock Surge Over 90% Today?
The primary driver for the rally was the announcement of successful results from the ONWARD1 and ONWARD2 Phase 3 trials.
These studies evaluated envudeucitinib, an oral medication, against both a placebo and apremilast. The data showed the drug met its primary and secondary endpoints with high statistical significance.
Investor enthusiasm was further fueled by the rapid onset of the drug's efficacy.
Clinical data indicated that envudeucitinib separated from the placebo by Week 4. This performance led to a sharp reversal in retail sentiment, which shifted from “bearish” to “extremely bullish” on social platforms like Stocktwits.
Deeper Dive: Envudeucitinib's “Class-Leading” Phase 3 Results
In the clinical trials, approximately 65% of patients achieved PASI 90, representing a 90% reduction in psoriasis symptoms by Week 24.
Furthermore, more than 40% of participants achieved complete skin clearance, known as PASI 100.
As reported by GlobeNewswire, 74% of patients reached PASI 75 by Week 16.
Alumis Chief Medical Officer Dr. Jörn Drappa noted that these results rank among the strongest reported for an oral therapy.
CEO Martin Babler added that the clinical profile positions the drug at the “forefront of next-generation TYK2 inhibitors.” The drug also maintained a favorable safety profile, with common side effects limited to mild headaches and respiratory infections.
How Are Analysts Reacting to Alumis's Breakthrough?
Wall Street analysts responded to the data with significant price target increases.
Oppenheimer analyst Jeff Jones described the results as “compelling,” raising the firm's price target from $25 to $50. Jones highlighted that envudeucitinib might hold an advantage over competitors like Takeda’s icotrokinra, which may require fasting.
Other firms maintained their optimistic outlooks following the news. Wells Fargo & Company reissued an “overweight” rating on ALMS shares.
Earlier in December, HC Wainwright had already signaled confidence by raising its target from $14 to $20 while issuing a “buy” rating.
ALMS Against the Field: Competitive Landscape in Psoriasis
While the broader biotechnology industry average rose around 3.5% on Tuesday, Alumis far outpaced its peers.
Competitors such as Structure Therapeutics (GPCR) and Inhibrx Biosciences (INBX) saw modest gains of around 1.5%, while Immunocore Holdings (IMCR) declined slightly.
The psoriasis market is crowded with established treatments from Johnson & Johnson and Protagonist Therapeutics.
However, Leerink Partners analyst Thomas Smith views envudeucitinib’s efficacy as “potentially class-leading.” Analysts suggest that if the drug maintains this clinical profile, it could capture significant market share from existing oral therapies.
What Recent Insider and Investor Activity Preceded the Surge?
The surge was preceded by notable insider activity and shifts in institutional sentiment.
On December 5, 2025, Director Srinivas Akkaraju acquired 186,377 shares. Major shareholder Foresite Capital Management VI also engaged in insider buying in late November, signaling internal confidence ahead of the Phase 3 data release.
However, not all sentiment was positive leading into the new year. Weiss Ratings had reaffirmed a “sell” rating on the stock as recently as late December 2025.
Wall Street Zen had also previously held a “sell” rating before upgrading the company to “hold” earlier in December.
Is Alumis (ALMS) a Strong Buy After This Rally?
Bulls argue that the Phase 3 results have significantly de-risked the company's valuation.
The strong efficacy data and favorable safety profile provide a clear path toward regulatory approval. Additionally, the stock has gained more than 305% over the last three months, showing strong momentum.
Conversely, some risks remain for investors to consider.
The company still faces a lengthy regulatory process and intense competition from pharmaceutical giants.
Some analysts also point to the lack of available market capitalization data and the company's previous history of “sell” ratings as reasons for caution despite the current rally.
What's Next for Alumis and ALMS Investors?
The company has set a clear timeline for the next two years.
Alumis plans to submit its New Drug Application to the FDA in the second half of 2026. This filing is a critical milestone that will determine the drug's path to commercialization.
Investors are also looking forward to results from the Phase 2b LUMUS trial.
This study evaluates envudeucitinib for the treatment of systemic lupus erythematosus, with topline data expected in the third quarter of 2026. These upcoming catalysts will likely remain the primary focus for shareholders through the end of the year.
The Bottom Line
Alumis Inc. has transformed its market position with “class-leading” data that challenges established oral psoriasis treatments.
While the nearly 91% single-day gain reflects massive investor confidence, the company's long-term success depends on its upcoming 2026 FDA submission and its ability to compete with industry leaders.
For now, the successful Phase 3 trials have provided the clinical validation necessary to fuel one of the sector's largest rallies of the year.
Read More
- Best Stock Screener Apps & Softwares
- Best Charting Tools For Traders
- How to Pick Stocks: A Beginner’s Guide to Smart Investing
- 10 Questions Smart Investors Ask Before Buying Stock
- How to Trade Stocks: A Beginner’s Guide to Buying and Selling Shares
